Double Or Second Antibody Patents (Class 436/540)
  • Patent number: 8993246
    Abstract: A bioassay employing a first group including a lanthanide ion carrier chelate and a first recognition element, a second group including an antenna ligand and a second recognition element; where the lanthanide ion carrier chelate binds strongly to lanthanide, or the lanthanide ion carrier chelate binds moderately to lanthanide, and an agent complexing the lanthanide ion is additionally employed at a concentration of at least 1 pmol/l. The antenna ligand binds weakly to the lanthanide ion. Analyte recognition by the first recognition element and by the second recognition element results in either chelate complementation and increased fluorescence, or chelate discomplementation and decreased fluorescence.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: March 31, 2015
    Assignee: Oy Arctic Partners AB
    Inventors: Tero Soukka, Urpo Lamminmaki
  • Patent number: 8877516
    Abstract: The invention features methods and devices for the detection of biomarker complexes and their components and for the sequential detection of multiple epitopes of a biomarker. The invention also features methods for diagnosing disease and evaluating the efficacy of treatment of a subject with a disease.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: November 4, 2014
    Assignee: Axela, Inc.
    Inventors: Yixin Lin, Jean-François Houle
  • Patent number: 8828671
    Abstract: Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding. The assay allows for whole cell analysis and even analysis of mixed populations of cells, yet provides detailed kinetic assessment of drug activity.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: September 9, 2014
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Norman B. Purvis, Gregory T. Stelzer
  • Patent number: 8828738
    Abstract: The invention is directed to methods and devices for reducing interference from heterophile antibodies in an analyte immunoassay. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with non-human IgM or fragments thereof by dissolving into said sample a dry reagent to yield a non-human IgM concentration of at least about 20 ?g/mL or equivalent fragment concentration; and (b) performing an electrochemical immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG or fragments thereof in addition to the IgM of fragments thereof.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: September 9, 2014
    Assignee: Abbott Point of Care Inc.
    Inventors: John Lewis Emerson Campbell, John Emegbero Omakor
  • Patent number: 8822229
    Abstract: The inventions provides a method for immunologically determining a keratan sulfate level which method includes bringing an anti-keratan sulfate monoclonal antibody into contact with a biological sample, the anti-keratan sulfate monoclonal antibody exhibiting a relative reaction specificity between keratan sulfate-I and keratan sulfate-II represented by IC50KS-I/KS-II of 0.4 to 5, to thereby provide a signal; and detecting keratan sulfate contained in the biological sample from the signal. On the basis of the method, the invention also provides a joint disease detection method and a method for assessing the effect of a remedy for a joint disease and a candidate substance therefor. Through these methods, a very small amount of keratan sulfate contained in a sample, can be determined. Particularly, these methods can determine, at high-sensitivity and high-specificity, the total keratan sulfate including keratan sulfate-I, which have been difficult to determine through a conventional technique.
    Type: Grant
    Filed: December 24, 2009
    Date of Patent: September 2, 2014
    Assignee: Seikagaku Corporation
    Inventors: Shigeyuki Wakitani, Hiroshi Fujita, Takeshi Ishimaru, Koji Yamamoto, Yasuhiro Kurahashi, Junichi Onaya, Hiroyuki Masuda
  • Patent number: 8709792
    Abstract: A method and device for detecting analytes in a test sample. Embodiments include methods for quantitatively detecting analytes within a range of concentrations. In an embodiment the method includes a lateral flow test strip with multiple test areas for capturing a labeled receptor to provide a detectable signal.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: April 29, 2014
    Assignee: Charm Sciences, Inc.
    Inventors: Steven J. Saul, Mark E. Tess, Robert J. Markovsky
  • Patent number: 8663985
    Abstract: An anchoring/capturing system for selecting or analyzing a CHO cell according to a product secreted by the CHO cell is described. The anchoring/capturing system comprises a first antibody or a first antigen-binding fragment for anchoring to the extracellular surface of the CHO cell, and a second antibody or a second antigen-binding fragment for binding the secreted product. Uses and methods involving the anchoring/capturing system are provided.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: March 4, 2014
    Assignee: Miltenyi Biotec GmbH
    Inventors: Stefan Miltenyi, Susanne Hoher-Peters, Monika Winkels
  • Patent number: 8603828
    Abstract: Hemoglobin, its variants, and glycated forms of each are determined individually in a multiplex assay that permits correction of the measured level of HbA1c to account for glycated variants and other factors related to the inclusion of the variants in the sample. New antibodies that are particularly well adapted to the multiplex assay are also provided.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: December 10, 2013
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Roger Walker, Benedicte Jardin
  • Patent number: 8486721
    Abstract: Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample with magnetic sacrificial beads opsonized to leukocytes, binding leukocytes in the sample to the magnetic sacrificial beads, and magnetically retaining the beads out of contact from an immunosensor.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: July 16, 2013
    Assignee: Abbott Point of Care Inc.
    Inventors: John Lewis Emerson Campbell, Graham Davis
  • Patent number: 8409818
    Abstract: The invention provides kits and methods for detecting or monitoring the number of cells in sample. The cell comprises a cell surface associated protein (CSAP) comprising a cytoplasmic (cytosolic) and an extracellular (ecto) domain. The kit comprises: (i) a chromatographic device; and (ii) a CSAP-binding agent. The method comprises: (i) optionally contacting the sample with an agent capable of lysing or permeabilizing CSAP bearing cells; (ii) contacting the sample with a CSAP-binding agent that binds to the cytoplasmic domain of the CSAP; and (iii) directly or indirectly evaluating the level or presence of bound CSAP in the sample.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: April 2, 2013
    Assignee: The Macfarlane Burnet Institute for Medical Research and Public Health Limited
    Inventors: David Andrew Anderson, Robyn Elizabeth Lloyd, Suzanne Mary Crowe, Mary Louise Garcia, Alan Lee Landay
  • Patent number: 8394325
    Abstract: Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample with magnetic sacrificial beads opsonized to leukocytes, binding leukocytes in the sample to the magnetic sacrificial beads, and magnetically retaining the beads out of contact from an immunosensor.
    Type: Grant
    Filed: June 14, 2010
    Date of Patent: March 12, 2013
    Assignee: Abbott Point of Care Inc.
    Inventors: John Lewis Emerson Campbell, Graham Davis
  • Patent number: 8389293
    Abstract: The invention is directed to methods and devices for reducing interference from leukocytes in competitive analyte immunoassays. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with sacrificial beads opsonized for leukocytes; and (b) performing a competitive immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG-coated sacrificial beads.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: March 5, 2013
    Assignee: Abbott Point of Care Inc.
    Inventors: John Lewis Emerson Campbell, Graham Davis
  • Patent number: 8377669
    Abstract: The invention is directed to methods and devices for reducing interference from leukocytes in an analyte immunoassay, and in particular in non-competitive immunoassays. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with sacrificial beads; and (b) performing a non-competitive immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG-coated sacrificial beads.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: February 19, 2013
    Assignee: Abbott Point of Care Inc.
    Inventors: John Lewis Emerson Campbell, Adam Roger Moss, Graham Davis
  • Patent number: 8361808
    Abstract: Methods, materials, apparatus and systems are described for performing capillary flow assay. In one aspect, a system includes a sample collection unit to collect a sample liquid and a sample testing and storing unit to interface with the sample collection unit to test and store the collected sample liquid. The sample testing and storing unit includes a sample inlet shaped to receive the collected sample from the sample collection unit, and a sample well positioned below the sample inlet to retain at least a portion of the sample liquid. The sample testing and storing unit includes a sample housing unit to store a remainder of the sample liquid not retained in the sample well, and an analyte testing unit housing shaped to receive an analyte detecting unit to test a presence of a target analyte in the sample liquid.
    Type: Grant
    Filed: December 30, 2009
    Date of Patent: January 29, 2013
    Assignee: Oranoxis, Inc.
    Inventor: Dequn Wang
  • Patent number: 8338189
    Abstract: The invention features methods and devices for the detection of biomarker complexes and their components and for the sequential detection of multiple epitopes of a biomarker. The invention also features methods for diagnosing disease and evaluating the efficacy of treatment of a subject with a disease.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: December 25, 2012
    Assignee: Axela Inc.
    Inventors: Yixin Lin, Jean-Francois Houle
  • Patent number: 8206939
    Abstract: The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: June 26, 2012
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Omar D. Perez, Garry P. Nolan, Jonathan M. Irish
  • Patent number: 8198037
    Abstract: The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: June 12, 2012
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Omar D. Perez, Garry P. Nolan
  • Patent number: 8173382
    Abstract: The invention provides among other things methods and kits based on assaying for cardiac troponin autoantibodies, either in conjunction with an assay for cardiac troponin and/or as an independent indicator of cardiac pathology, such as myocarditis, cardiomyopathy, and/or ischemic heart disease. Assay methods of the invention can be employed among other things to identify cardiac pathology, or risk thereof, in subjects who have an autoimmune disease or who are related to an individual with an autoimmune disease. In particular embodiments, the invention also provides a method of determining whether a subject having, or at risk for, a cardiac pathology is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: May 8, 2012
    Assignee: Abbott Laboratories
    Inventors: Phillip G. Mattingly, Maciej Adamczyk, Roy Jeffrey Brashear, Robert C. Doss
  • Patent number: 8168394
    Abstract: The invention relates to a method for detecting, in vitro, an infection with a microorganism, such as the hepatitis C virus, in a biological sample, by simultaneously detecting an antigen of this microorganism and the antibodies against this same antigen, and also to the reagents and kits implementing this method.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: May 1, 2012
    Assignee: Bio-Rad Pasteur
    Inventors: François Rieunier, Muriel Feyssaguet, Stéphanie Henriot, Nadine Lambert
  • Patent number: 8148094
    Abstract: The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: April 3, 2012
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Garry P. Nolan, Omar D. Perez
  • Patent number: 8137987
    Abstract: Bodily fluid is analyzed for the presence of drugs of a selected panel of drugs in a simultaneous assay in which sample of the fluid is incubated with additional amounts of all drugs of the panel, antibodies specific to each of the drugs of the panel, and microparticles, the microparticles being divided into subsets, one subset for each drug in the panel and each subset distinguishable from the others. The incubation is performed in a liquid medium in which competitive binding occurs, the drugs in the sample competing with those added to the assay medium for binding to the antibodies. In one procedure, the added drugs are pre-coupled to the microparticles while the antibodies are not, and the incubation is followed by further incubating the microparticles with labeled ligands that have affinity for the antibodies.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: March 20, 2012
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: William F. Link, Renato B. del Rosario, Randy V. Sweet, David L. King
  • Patent number: 8114617
    Abstract: The invention involves a method for measuring phosphorylation of proteins at specific sites and, as such, is an indicator of the protein kinase activity of enzymes capable of phosphorylating those sites. The method involves the in vitro or in vivo phosphorylation of a target protein at a specific serine, threonine or tyrosine residue, subjecting that protein (non-phosphorylated) to reaction mixture containing all reagents, including phosphokinase which allow the creation of a phosphorylated form of protein. The phosphorylated protein is measured by contacting it with an antibody specific for the phosphorylation site(s). The invention includes antibodies useful in practicing the methods of the invention. The invention particularly relates to all proteins modified by phosphorylation and dephosphorylation as illustrated by Tau, Rb and EGFR proteins and antibodies specific for the site of phosphorylation of the Tau, Rb or EGFR proteins.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: February 14, 2012
    Assignee: Life Technologies Corporation
    Inventors: Kevin J. Reagan, Erik Schaefer, Jimin Wang
  • Patent number: 8058022
    Abstract: Disclosed are methods for detecting protein complexes of sigma factors and interacting proteins in a sample containing Mycobacterium tuberculosis. Such methods are useful for the diagnosis and/or monitoring of tuberculosis in a subject. Also disclosed are methods for screening compounds that affect the interaction of one or more sigma factors with one or more interacting proteins.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: November 15, 2011
    Assignee: Indian Institute of Science
    Inventor: Balsubramanian Gopal
  • Patent number: 7947465
    Abstract: Bodily fluid is analyzed for the presence of drugs of a selected panel of drugs in a simultaneous assay in which sample of the fluid is incubated with additional amounts of all drugs of the panel, antibodies specific to each of the drugs of the panel, and microparticles, the microparticles being divided into subsets, one subset for each drug in the panel and each subset distinguishable from the others. The incubation is performed in a liquid medium in which competitive binding occurs, the drugs in the sample competing with those added to the assay medium for binding to the antibodies. In one procedure, the added drugs are pre-coupled to the microparticles while the antibodies are not, and the incubation is followed by further incubating the microparticles with labeled ligands that have affinity for the antibodies.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: May 24, 2011
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: William F. Link, Renato B. del Rosario, Randy V. Sweet, David L. King
  • Patent number: 7919331
    Abstract: The invention describes immunochromatographic protocols in which one or more analytes, such as a bacteria or virus, can be assayed utilizing a “sandwich” complex.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: April 5, 2011
    Assignee: Silver Lake Research Corporation
    Inventor: Mark S. Geisberg
  • Patent number: 7888050
    Abstract: The invention involves a method for measuring phosphorylation of proteins at specific sites and, as such, is an indicator of the protein kinase activity of enzymes capable of phosphorylating those sites. The method involves the in vitro or in vivo phosphorylation of a target protein at a specific serine, threonine or tyrosine residue, subjecting that protein (non-phosphorylated) to reaction mixture containing all reagents, including phosphokinase which allow the creation of a phosphorylated form of protein. The phosphorylated protein is measured by contacting it with an antibody specific for the phosphorylation site(s). The invention includes antibodies useful in practicing the methods of the invention. The invention particularly relates to all proteins modified by phosphorylation and dephosphorylation as illustrated by Tau, Rb and EGFR proteins and antibodies specific for the site of phosphorylation of the Tau, Rb or EGFR proteins.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: February 15, 2011
    Assignee: Life Technologies Corporation
    Inventors: Kevin Reagan, Erik Schaefer, Jimin Wang
  • Patent number: 7807389
    Abstract: Disclosed are compositions and methods related to joint inflammation diseases. Disclosed is the relationship between osteoclasts and inflammatory joint diseases and osteoclast precursor cells.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: October 5, 2010
    Assignee: University of Rochester
    Inventors: Christopher T. Ritchlin, Sally A. Haas-Smith, Edward M. Schwarz
  • Patent number: 7785898
    Abstract: The present invention provides methods for identifying and/or enriching fetal cells from maternal blood, using as fetal cell markers the antibodies that the mother produces against paternally inherited fetal antigens. The fetal cell-maternal antibody complexes are identified and isolated using labelled agents that bind to the maternal antibodies. The present invention also provides fetal cells, isolated by use of said maternal antibodies, as a source of fetal DNA for prenatal genetic diagnosis of the fetus.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: August 31, 2010
    Assignee: Genetic Technologies Limited
    Inventor: Ralph M. Bohmer
  • Patent number: 7776605
    Abstract: The invention provides among other things methods and kits based on assaying for cardiac troponin autoantibodies, either in conjunction with an assay for cardiac troponin and/or as an independent indicator of cardiac pathology, such as myocarditis, cardiomyopathy, and/or ischemic heart disease. Assay methods of the invention can be employed among other things to identify cardiac pathology, or risk thereof, in subjects who have an autoimmune disease or who are related to an individual with an autoimmune disease. In particular embodiments, the invention also provides a method of determining whether a subject having, or at risk for, a cardiac pathology is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: August 17, 2010
    Assignee: Abbott Laboratories
    Inventors: Phillip G. Mattingly, Maciej Adamczyk, Roy Jeffrey Brashear, Robert C. Doss
  • Patent number: 7732126
    Abstract: The present invention is directed to a new bone marrow stromal stem cell (BMSSC) marker, CD18, for use in selecting a population of cells enriched in BMSSCs, from bone marrow cells, adipose cells, or peripheral blood. The invention is further directed to methods for selecting a population of cells enriched in BMSSCs based on the selective expression of CD18 on their surface, using techniques known in the art such as fluorescent assisted cell sorting, an immunomagnetic method, flow microfluorimetry, immunofluorescence, immunoperoxidase staining, radioimmunoassay and immunoaffinity chromatography. The invention is further directed to the BMSSCs isolated based on CD18 expression, and their use to treat various diseases. In one aspect, the HMSSCs are transformed with a vector having a normal gene for CD18, and the transformed BMSSCs are administered to treat bone degenerative diseases and diseases of bone involving abnormal expression of CD18 expression of CD18.
    Type: Grant
    Filed: September 6, 2005
    Date of Patent: June 8, 2010
    Assignee: University of Maryland, Baltimore
    Inventors: Li Zhang, Yasuo Miura, Songtao Shi
  • Patent number: 7723045
    Abstract: This invention provides novel assays for the detection of dysfunctional HDL. The assays are good diagnostics and/or prognostics for atherosclerosis or other pathologies characterized by an inflammatory response. In certain embodiments the methods involve measurements of heme-related HDL-associated proteins (e.g., haptoglobin, hemopexin, etc.), and/or measurements of the relative distribution of HDL-associated proteins between HDL and the non-lipoprotein fractions of plasma/serum, and/or measurements of the ability of pro-inflammatory HDL to consume nitric oxide, and/or measurement of the ability of HDL to inhibit LDL aggregation.
    Type: Grant
    Filed: February 8, 2007
    Date of Patent: May 25, 2010
    Assignee: The Regents of the University of California
    Inventors: Alan M. Fogelman, Srinivasa T. Reddy
  • Patent number: 7718444
    Abstract: This invention provides a simple detection method with excellent sensitivity and specificity, which allows prompt detection of an analyte by allowing a labeled reagent to effectively react with the analyte in the process of treating an analyte-containing specimen, such as during removal of impurities, a detection apparatus, and a detection kit. This method for detecting an analyte in specimens comprises steps of: bringing a labeled reagent containing a ligand that specifically binds to the analyte into contact with a specimen; and supplying the mixture of the specimen and the labeled reagent to a solid-phase support onto which a capture reagent that specifically binds to the analyte has been immobilized, wherein the step of bringing the specimen into contact with the labeled reagent is carried out at a site that is not on the solid-phase support and that is detached from the solid-phase support.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: May 18, 2010
    Assignee: Denka Seiken Co., Ltd.
    Inventors: Kazuyuki Takizawa, Ryo Shida
  • Patent number: 7718388
    Abstract: The present invention relates to methods for detecting or quantifying an analyte in a test sample including providing at least one test mixture including a test sample, at least one marker complex, wherein each marker complex includes a particle, a marker, and one member of a coupling group, a first binding material selected to bind to a portion of the analyte, a second binding material selected to bind with a portion of the analyte other than the portion of the analyte for which the first binding material is selected, analyte analog, and/or marker conjugate. The at least one test mixture is passed through a membrane. The amount of marker on the membrane is detected and correlated to the presence or amount of analyte in the test sample.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: May 18, 2010
    Assignee: Cornell Research Foundation, Inc.
    Inventor: Antje J. Baeumner
  • Patent number: 7695924
    Abstract: The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.
    Type: Grant
    Filed: January 18, 2007
    Date of Patent: April 13, 2010
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Omar D. Perez, Garry P. Nolan
  • Patent number: 7695919
    Abstract: A method for analyzing a biological sample by antibody profiling for identifying forensic samples or for detecting the presence of an analyte. In an embodiment of the invention, the analyte is a drug, such as marijuana, Cocaine (crystalline tropane alkaloid), methamphetamine, methyltestosterone, or mesterolone. The method comprises attaching antigens to a surface of a solid support in a preselected pattern to form an array wherein locations of the antigens are known; contacting the array with the biological sample such that a portion of antibodies in the sample reacts with and binds to the antigens in the array to form immune complexes; washing away antibodies that do form immune complexes; and detecting the immune complexes, to form an antibody profile. Forensic samples are identified by comparing a sample from an unknown source with a sample from a known source.
    Type: Grant
    Filed: March 26, 2007
    Date of Patent: April 13, 2010
    Assignee: Battelle Energy Alliance, LLC
    Inventors: William A. Apel, Vicki S Thompson
  • Patent number: 7638292
    Abstract: A method for detection and/or quantification of cardiac troponin I (cTnI) in a sample derived from an individual's blood, the method being based on a sandwich immunoassay employing at least two capture antibodies and at least one tracer antibody, in which a first capture antibody is directed to the N-terminal part of cTnI, to the C-terminal part of cTnI or to the part of the cTnI midfragment, which is slightly affected by the interfering factor, and a second capture antibody is directed to another of these parts, and a tracer antibody is directed to the N-terminal part of cTnI, to the C-terminal part of cTnI or to TnC, which is complexed with cTnI.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: December 29, 2009
    Assignee: University of Turku
    Inventors: Susann Eriksson, Kim Pettersson
  • Patent number: 7632686
    Abstract: The instant invention provides an economical flow-through method for determining amount of target proteins in a sample. An antibody preparation (whether polyclonal or monoclonal, or any equivalent specific binding agent) is used to capture and thus enrich a specific monitor peptide (a specific peptide fragment of a protein to be quantitated in a proteolytic digest of a complex protein sample) and an internal standard peptide (the same chemical structure but including stable isotope labels). Upon elution into a suitable mass spectrometer, the natural (sample derived) and internal standard (isotope labeled) peptides are quantitated, and their measured abundance ratio used to calculate the abundance of the monitor peptide, and its parent protein, in the initial sample.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: December 15, 2009
    Assignee: Anderson Forschung Group
    Inventor: Norman L. Anderson
  • Patent number: 7604952
    Abstract: A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient.
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: October 20, 2009
    Assignee: Leuven Research & Development VZW
    Inventors: Paul N. Holvoet, Désiré J. Collen
  • Patent number: 7595202
    Abstract: The present invention provides a method for controlling the spatial arrangement of an energy donor and an energy acceptor in a reaction complex in order to carry out the measurement with good precision and high sensitivity, and a measurement system using the method. Two types of material having affinity for the subject material to be measured are respectively labeled with a combination of reporters that give rise to energy transfer; those that have been thus obtained by labeling these materials are each further labeled with materials that have weak affinity for each other to give reagents, which are then mixed with a sample to give the reaction complex. Each of the materials is brought into spatial proximity by binding based on the affinity among the materials having weak affinity for each other in the reaction complex, and since that condition is stably maintained, a more efficient energy transfer occurs.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: September 29, 2009
    Assignees: Eiken Nagaku Kabushiki Kaisha
    Inventors: Teruyuki Nagamune, Hiroshi Ueda, Yoshiyuki Ohiro, Norio Shibata
  • Patent number: 7569398
    Abstract: The present invention relates to a method of transporting an analyte present in a sample, to a method of concentrating an analyte present in a sample, and to a device for implementing these methods. In the method of transporting an analyte present in a sample of the present invention, a solution A in which the analyte is attached to magnetic particles is prepared from the sample; the solution A is introduced into a first container connected via a bottleneck to a second container; and the analyte attached to the magnetic particles is moved, by means of a magnetic system, from the first container to the second container via the bottleneck, the second container being filled with all or part of the solution A and/or with another solution.
    Type: Grant
    Filed: November 27, 2001
    Date of Patent: August 4, 2009
    Assignee: Commissariat a l'Energie Atomique
    Inventors: Pierre Puget, Patrick Pouteau, Frédéric Ginot, Patrice Caillat
  • Patent number: 7566573
    Abstract: A method and a kit for determining the presence or amount of analytes in samples over a broad potential concentration range for the analyte. The method and kit incorporate chemiluminescent and fluorescent labels conjugated to a specific binding partner for the analyte for sandwich assays, or to the analyte or an analog of the analyte for competitive assays. The conjugates are mixed with the sample and the labels are detected simultaneously or sequentially.
    Type: Grant
    Filed: December 19, 2005
    Date of Patent: July 28, 2009
    Assignee: Idexx Laboratories, Inc.
    Inventors: Charles R. Carpenter, Giosi Farace, Paul Scott MacHenry, Brian John Foster, Mirolee Blue Zieba, Michael Ryan D'Angelo
  • Patent number: 7563584
    Abstract: The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: July 21, 2009
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Omar D. Perez, Garry P. Nolan
  • Patent number: 7547554
    Abstract: The invention relates to a method and a device for detecting very small quantities of particles. The inventive method is based on a detection of antigen-antibody reaction products and provides a very high detection sensitivity all the way to the femtomolar or attomolar range.
    Type: Grant
    Filed: September 9, 2004
    Date of Patent: June 16, 2009
    Inventor: Constantin Odefey
  • Patent number: 7537938
    Abstract: A method is provided for detecting biomarkers in rare circulating cells by forming an enriched population of cells immunomagnetically followed by biomarker detection using binding compounds having releasable molecular tags. Preferably, biomarkers comprising one or more protein-protein complexes are detected in circulating cancer cells metastasized from a solid tumor. In the presence of biomarkers, the molecular tags of the binding compounds are released and separated from the assay mixture for detection and/or quantification.
    Type: Grant
    Filed: January 26, 2004
    Date of Patent: May 26, 2009
    Assignee: Monogram Biosciences, Inc.
    Inventors: Hrair Kirakossian, Thomas Klopack, Sharat Singh
  • Patent number: 7537907
    Abstract: A method of single parameter and multiparameter characterizing of cells, particularly immunophenotyping of cells, is provided. The method preferably uses antibody coated microspheres which are adapted to bind to specific types of cells. One or more sets of coated microspheres are added simultaneously or sequentially to a suspension of cells and bind the cells they are adapted to bind. Cells may bind to one or more microspheres. The suspension is then filtered to trap bead-cell complexes. The complexes are preferably stained and then examined to characterize the cells, preferably the cells bound to the microspheres. A kit and apparatus for performing the method are also provided.
    Type: Grant
    Filed: February 6, 2008
    Date of Patent: May 26, 2009
    Inventor: Dan A. Pankowsky
  • Patent number: 7510881
    Abstract: A method and kit for quantitatively and/or qualitatively detecting one or more components in samples, including the use of metal-particle labelled reagents and an antibody conjugate are disclosed. The components are capable of binding to a probe. A kit and method for staining components in cell and tissue sections, based upon the detection method, are also disclosed.
    Type: Grant
    Filed: August 25, 2003
    Date of Patent: March 31, 2009
    Inventors: Marc Ramael, Jean-Paul Sanders
  • Patent number: 7416855
    Abstract: Disclosed are human interleukin-1 ? converting enzyme like apoptosis proteases-3 and 4 and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Also provided are methods of using the polypeptides, for example, as an antitumor agent, and antiviral agent, and antibodies and antagonists against such polypeptides for example, for treating Alzheimer's disease, Parkinson's disease, rheumatoid arthritis and head injury. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases are also disclosed.
    Type: Grant
    Filed: March 17, 2004
    Date of Patent: August 26, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventors: Wei-Wu He, Craig A. Rosen, Peter L. Hudson, Gregg A. Hastings
  • Patent number: 7390626
    Abstract: ELISA, Western Blot, and a peptide-based ELISA were applied to clinical specimens from patients with clinical symptoms of tick borne diseases, including Lyme disease. Peptides from different components of Borrelia during different cycles, including peptides from outer surface protein, leukocyte function associated antigens, immunodominant antigens, variable major proteins, and peptides from decorin-binding proteins of Borrelial subspecies (B. sensu stricto. B. afzelii, B. garinii) were used. Antibodies against specific peptides from Babesia and Ehrlichia were also measured.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: June 24, 2008
    Assignee: Immunosciences Lab., Inc.
    Inventor: Aristo Vojdani
  • Patent number: RE43979
    Abstract: The invention relates to a method for detecting specific target-cells in a simple and time saving way, using paramagnetic particles, antibodies recognizing the Fc portions of target-cell associating antibodies and target-cell associating antibodies directed to specific antigen determinants in the target-cell membranes. Incubation of the cell suspension with a mild detergent and/or second set of antibodies or antibody fragments, prelabeled or not with fluorescent agents, metallocolloids, radioisotopes, biotincomplexes or certain enzymes allowing visualization, with dramatically increase the specificity of the method. The method can further be used for isolation of the target-cells by magnetic field application and kit for performing the method according to the invention is described.
    Type: Grant
    Filed: February 5, 2003
    Date of Patent: February 5, 2013
    Assignee: Abbott Laboratories
    Inventors: Oystein Fodstad, Gunnar Kvalheim
  • Patent number: RE44031
    Abstract: A method for analyzing a biological sample by antibody profiling for identifying forensic samples or for detecting the presence of an analyte. In an embodiment of the invention, the analyte is a drug, such as marijuana, Cocaine (crystalline tropane alkaloid), methamphetamine, methyltestosterone, or mesterolone. The method comprises attaching antigens to a surface of a solid support in a preselected pattern to form an array wherein locations of the antigens are known; contacting the array with the biological sample such that a portion of antibodies in the sample reacts with and binds to the antigens in the array to form immune complexes; washing away antibodies that do form immune complexes; and detecting the immune complexes, to form an antibody profile. Forensic samples are identified by comparing a sample from an unknown source with a sample from a known source.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: February 26, 2013
    Assignee: Battelle Energy Alliance, LLC
    Inventors: William A. Apel, Vicki S. Thompson